Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03578783 · ClinicalTrials.gov registry record · Phase 2
PSD502 in Subjects With Premature Ejaculation
A Phase 2 study, sponsored by Plethora Solutions.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT03578783: Completed Phase 2 study, sponsored by Plethora Solutions.
NCT03578783 is a Phase 2 study that has completed, run by Plethora Solutions. The registered enrollment target is 121 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03578783, a Phase 2 study, has completed, sponsored by Plethora Solutions.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
This study is being done to test the effect of PSD502 (the study medication) compared to placebo in subjects with premature ejaculation. PSD502 is a topical (applied to skin) anesthetic spray containing a mixture of two drugs called lidocaine and prilocaine that will be applied to the penis. Half of the subjects will receive PSD502 and half will receive placebo.
Primary Outcome
Success is defined as having a 1-point or greater improvement between the mean response over the treatment period and the mean response during the baseline period
Interventions
- DRUG Placebo
- DRUG PSD502
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2018-12-26 |
| Est. Completion | 2021-12-01 |
| Phase | Phase 2 |
What the finished NCT03578783 record still lists
NCT03578783 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03578783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03578783 about?
NCT03578783 is a clinical study titled "PSD502 in Subjects With Premature Ejaculation". This study is being done to test the effect of PSD502 (the study medication) compared to placebo in subjects with premature ejaculation. PSD502 is a topical (applied to skin) anesthetic spray containing a mixture of two drugs called lidocaine and prilocaine that will be applied to the penis. Half of...
What is the current status of trial NCT03578783?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2018-12-26. Estimated completion is 2021-12-01.
What interventions are being tested in trial NCT03578783?
The interventions under investigation include: Placebo (DRUG), PSD502 (DRUG).
Who is sponsoring clinical trial NCT03578783?
This trial is sponsored by Plethora Solutions, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03578783's enrollment target sits among peer trials
121 567th of 2000 higher than 1,432 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI